Although the role of CD248 in the pathogenesis of SSc has not yet been established, its potential role in controlling vessel regression and fibrosis makes this molecule a potential therapeutic target in a clinical setting, different from cancer, and in which an effective therapeutic approach to prevent fibrosis is still an important unmet need. This evidence concerns the gene CD248 and cancer.